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SUMMARY 54 
 Despite significant advances in the understanding of the host response to chlamydial 55 
infection and over 30 years of vaccine research, Chlamydia trachomatis remains the leading 56 
cause of bacterial sexually transmitted disease worldwide. This  gram-negative obligate 57 
intracellular bacterium, that often remains asymptomatic, may cause pelvic inflammatory 58 
disease (PID), ectopic pregnancies, scarring of the fallopian tubes, miscarriage and infertility 59 
when left untreated.  In the genital tract, Chlamydia trachomatis primarily infects epithelium 60 
cells and requires Th1 immunity for optimal clearance. This review first  focuses on the 61 
immune cells important in a chlamydial infection. Secondly, we will summarize the research 62 
and challenges associated with developing a chlamydial vaccine that elicits a protective Th1-63 
mediated immune response without inducing adverse immunopathologies. 64 
 65 
INTRODUCTION 66 
 Chlamydia trachomatis is the leading cause of bacterial sexually transmitted diseases 67 
in humans. According to the WHO in 2008, there was 105 million new cases of STDs each 68 
year due to C. trachomatis worldwide and the infection rate has been steadily increasing (9, 69 
103). When symptomatic, C. trachomatis can lead to mucopurulent endocervical discharge, 70 
hypertrophic cervix, and post coital bleeding. In 20-40% of untreated women C. trachomatis 71 
may reach the fallopian tubes via the endometrial epithelium and cause pelvic inflammatory 72 
disease (PID). However, C. trachomatis genital tract infections are often asymptomatic (75-73 
90%) and therefore remain undiagnosed and untreated. This can lead to tubal factor infertility 74 
or ectopic pregnancies (68, 69), which is a life threatening condition. C. trachomatis can be 75 
easily treated with antibiotics such as erythromycin, azithromycin or doxycycline. However, 76 
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several studies have documented that within a year after treatment for a C. trachomatis 77 
infection, 13-26% of individuals showed evidence of persistent or recurrent infections (38, 78 
51). Therefore, due to the high rate of asymptomatic infections, recurrent infections and the 79 
severity of pathologies induced by Chlamydia, the development of a vaccine is paramount. 80 
This review focuses on C. trachomatis and C. muridarum (a model organism that naturally 81 
infects rodents and largely used for animal experiments) immunity and the challenges 82 
associated with generating a vaccine against this bacterium. Table 1 summarizes recent 83 
developments in chlamydial research including Chlamydia strain or antigen used, cell type 84 
affected and immune response elicited.  85 
 86 
CHLAMYDIA BIOLOGY 87 
 The genus Chlamydia includes species that infect humans (C. trachomatis, C. 88 
pneumoniae), and animals (C. muridarum, C. suis, C. abortus) (21). Presently, there have 89 
been 18 identified serovars of C. trachomatis based on the reactivity of patient sera to the 90 
major outer membrane protein (MOMP) (135). Some serovars are associated with ocular 91 
tissue infections (A-C) while others primarily infect genital tissues (D-K) (7). C. trachomatis 92 
is a gram-negative obligate intracellular bacterium that in the genital tissues normally infects 93 
the epithelium layer of the cervix of women and the urethra of men (12).  94 
 Chlamydia exists in two developmental forms, the infectious extracellular non-95 
replicating elementary body (EB) and the non-infectious intracellular replicating reticulate 96 
body (RB). The EB displays no metabolic activity, is resistant to both chemical and physical 97 
factors, and is adapted for prolonged extracellular survival. Infection begins when the small 98 
(~0.2-0.3μm) EB attaches to the host cell and is internalized inside an entry vacuole which 99 
avoids fusion with the lysosome. After 8-10 hours the vesicle bound EB (termed an inclusion) 100 
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replicates by binary fission into the larger (~0.8 μm) RB (138). Following several rounds of 101 
division, the RB`s reorganize and revert back to the EB (131).  Inside host cells, C. 102 
trachomatis circumvents endogenous stress mechanisms, prevents lysosomal fusion and 103 
escapes intracellular destruction by replicating in an inclusion outside of the endocytic 104 
pathway (138). C. trachomatis-infected cells have increased inducible oxide synthase (iNOS) 105 
and increased pro-inflammatory molecules such as activins, which may be involved in 106 
scarring (1, 115).  107 
 108 
IMMUNITY TO CHLAMYDIA 109 
T cells 110 
 A critical role for T cells in immunity to Chlamydia was demonstrated almost 30 years 111 
ago when Rank et al. observed that athymic nude mice established chronic infection with C. 112 
muridarum after intravaginal inoculation whereas wild-type (wt) mice resolved the infection 113 
in 20 days (114). In human and mouse models, both CD4+ and CD8+ T cells can be detected 114 
at the site of C. trachomatis infection (65, 71, 101, 129). T cells are unable to recognize 115 
pathogens or antigens without the help of antigen presenting cells (APC) such as dendritic 116 
cells (DC), macrophages, or B cells. APC are able to phagocytose chlamydial EBs in the 117 
extracellular space or engulf infected cells harboring RBs. After phagocytosis, APC degrade 118 
chlamydial components and present the peptides via MHC class II-antigen complex to CD4 + 119 
T cells or MHC class I-antigen complex to CD8 + T cells. In fact, numerous C. trachomatis 120 
antigens have been identified which can be recognized by human CD4+ and CD8+ T cells 121 
including the cysteine-rich outer membrane protein 2 (Omp2) (40), polymorphic outer 122 
membrane protein D (POMP-D) (41), MOMP (50, 72, 104), heat shock protein 60 (hsp 60) 123 
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(25, 50), chlamydial protease activating factor (CPAF) (75), PmpG, PmpF, and RpIF (66, 124 
101). High-throughput proteomic screening has identified even more potential 125 
immunodominant C. trachomatis antigens including 36 that have been shown to react with 126 
sera from three strains of mice immunized with live Chlamydia and two protein antigens that 127 
were able to induce a polyfunctional Th1 CD4+ T cell response and high Th1 antibody titers 128 
(112, 126). Although Chlamydia is able to induce a Th2 response characterized by IL-4 and 129 
Th2-associated antibodies such as IgG1, a Th1 response predominates characterized by the 130 
production of IL-12 by APC (17) and the subsequent activation of  IFN-γ producing T cells 131 
and plasma B cells that secrete Th1-associated antibodies such as IgG2a and IgG3 (97, 100). 132 
However, a recent study demonstrated that CD4+ T cells from women with genital tract C. 133 
trachomatis infection that were restimulated ex vivo with inactivated (γ-irradiated) EB  secrete 134 
significantly more IL-4 than TNF-α and IFN-γ. This study suggests that the type of immune 135 
response  (Th1 vs Th2) to C. trachomatis may be tissue specific (132).  136 
 While there is ample evidence that CD4+ T cells play an integral part in the resolution 137 
of C. trachomatis and C. muridarum infections (34, 36, 39, 60), the role for CD8 + T cell has 138 
been controversial even though CD8+ T cells are induced following infection and Chlamydia-139 
specific human and mouse CD8+ T cells are cytotoxic for Chlamydia-infected target cells 140 
(137). A recent study by Murthy et al. demonstrated that wt and CD8+ T cell-deficient mice 141 
displayed similar clearance of C. muridarum following vaginal chlamydial challenge (92). 142 
These data support previous studies which  demonstrated that CD8+ T cells are not critical for 143 
C. trachomatis clearance (87, 88, 121). Furthermore, the CD8+ T cell-deficient mice 144 
demonstrated reduced oviduct pathology (hydrosalpinx) compared to wt, suggesting a role of 145 
CD8+ T cells in chlamydial pathogenesis (92). An interesting study demonstrated that the 146 
majority of CD8+ T cells in the cervix before and after a C. trachomatis infection do not 147 
express perforin (53). Perforin is a cytolytic protein found in the granules of CD8+ T cells 148 
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which forms a pore by inserting itself into the cells plasma membrane resulting in lysis of the 149 
target cell. Therefore,  the lack of perforin in endocervix CD8+ T cells may explain why 150 
CD8+ T cells do not play a critical role in the elimination of genital chlamydial infection. 151 
Although CD8+ T cells appear not to be critical in resolving a chlamydial infection and may 152 
even contribute to chlamydial sequelae, they nonetheless may play a contributory albeit 153 
secondary role by regulating other cells and by their own production of IFN-γ (137).  154 
Dendritic Cells 155 
 Dendritic cells (DC) are known to be the quintessential antigen presenting cells. 156 
Immature DC are highly phagocytic and after internalization of pathogens they degrade the 157 
components and present the peptides to T cells via MHC receptors activating the T cells and 158 
initiating a cell- mediated and / or humoral immune response. The capacity of DCs to present 159 
chlamydial antigens to T cells, secrete Th1 cytokines such as IL-12 and TNF-α and the 160 
importance of MHC class molecules in chlamydial infection has been demonstrated both in 161 
vitro and in vivo (64, 84, 87, 99, 122). An early study conducted by Lu and Zhong showed 162 
that bone marrow derived dendritic cells (BMDC) pulsed with heat-killed C. trachomatis  and 163 
adoptively transferred into a naive mouse was protective against a subsequent challenge with 164 
live C. trachomatis  in a mouse lung infection model (82). This protection was mediated by a 165 
Th1 response further demonstrating a correlation between Th1 skewed immunity and 166 
protection against chlamydial infection. In contrast, DCs that were pulsed with recombinant 167 
MOMP and adoptively transferred into mice elicited primarily the Th2-associated antibody 168 
IgG1 (119). Furthermore, IL-10 (Th2-associated cytokine) KO DC pulsed with UV-169 
inactivated C. trachomatis and adoptively transferred activated a high frequency of Th1 cells 170 
(47). These data have direct relevance to vaccine development because it indicates that the 171 
type of cytokines produced and antigens processed by the DC and presented to CD4+ T cells 172 
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is essential in the Th1/Th2 balance of the immune response to Chlamydia. There is also 173 
evidence that live Chlamydia is required for an optimal and protective immune response. Rey-174 
Ladino and colleagues demonstrated that the level of protection induced by DC pulsed with 175 
UV-inactivated C. trachomatis EB and adoptively transferred into mice was significantly less 176 
than in mice that were challenged with live EB pulsed DC (116). A more recent study 177 
discovered that murine DCs pulsed with live C. muridarum EBs presented 45 MHC class II 178 
peptides mapping 13 proteins whereas dead EBs presented only six MHC class II peptides 179 
mapping to three proteins (143). However, C. trachomatis has developed strategies to limit 180 
the presentation of these antigens to T cells by downregulating MHC expression on APC (54). 181 
C. trachomatis has been shown to inhibit MHC molecules within infected cells through the 182 
degradation of the MHC class I transcription factor RFX-5 and the MHC class II transcription 183 
factor USF-1 by secreting the chlamydial protease CPAF into the cytosol (29, 111, 145, 146).  184 
DC are important to vaccine research because they are the critical links between innate and 185 
adaptive immunity. Two recent studies using DC transfected with a recombinant adenovirus 186 
carrying C. trachomatis MOMP antigen (81) and DC pulsed ex vivo with recombinant C. 187 
trachomatis protease-like factor (rCPAF) (75) illustrate the ability of DC to induce protective 188 
immunity against genital C. trachomatis and C.muridarum challenge respectively. 189 
Macrophages 190 
 Studies using both C. trachomatis and C. muridarum have shown that macrophages 191 
are recruited to sites of infection (88) and are capable of phagocytosing Chlamydia (8). 192 
Macrophages are also a source of both proinflammatory cytokines such as IL-8, IL-6 and 193 
TNF-α (6, 141). However, unlike epithelial cells, macrophages are not a hospitable niche for 194 
chlamydial intracellular replication illustrated by the fact that compared to epithelial cells 195 
only a small fraction of chlamydial RBs are detected in macrophages (124). C. trachomatis 196 
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destruction inside the macrophage has been associated with host cell autophagy, a process by 197 
which cells degrade cytoplasmic proteins and organelles (2, 124, 140), and studies have 198 
demonstrated that macrophage autophagy can enhance antigen presentation to T cells (22). 199 
Furthermore, INF-γ has been shown to enhance both autophagy and upregulation of MHC 200 
class molecules in macrophages (2, 15). This is relevant because, in addition to activating 201 
primed T cells, there is evidence suggesting that macrophages are able to initiate a humoral 202 
response in naive mice (130). Therefore, enhanced upregulation of MHC molecules 203 
containing chlamydial antigens may induce T cells to initiate both a cell-mediated and 204 
antibody immune response against Chlamydia. However, Jendro et al. demonstrated that 205 
human macrophages infected with C. trachomatis can induce T cell apoptosis (61, 62). In 206 
addition to efficiently eliminating Chlamydia and presenting the peptides to T cells, 207 
macrophages may also have an  effect on chlamydial infection by inducing T cell death and 208 
perpetuating a persistent infection. 209 
B cells/Antibodies 210 
  Previous studies demonstrated that anti-Chlamydia antibodies correlated with 211 
protective immunity against C. trachomatis in humans (4, 59) and numerous C. trachomatis 212 
proteins have been shown to induce antigen specific antibodies (36). However, even though 213 
anti-Chlamydia antibodies are able to neutralize infection in vitro (5, 13) growing evidence 214 
show that B cells may not play a critical role in controlling a primary chlamydial infection but 215 
are important for a secondary memory response (89, 90). Several mechanisms have been 216 
proposed on how B cells contribute to immunity during re-infection. These mechanisms 217 
include antibody-mediated neutralization and opsonization (5), antibody-dependent cellular 218 
cytotoxicity (ADCC) (86) (a mechanism of cell-mediated immune defense whereby cells that 219 
have antibodies attached to their surface are targeted for lysis), and the formation of antigen-220 
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antibody complexes that bind Fc receptors on the APC which then enhances phagocytosis and 221 
antigen presentation to the CD4+ T cell (57). 222 
 Heat shock proteins (hsp), which are found in both eukaryotic and prokaryotic 223 
organisms, are stress-proteins that are involved in the correct folding of intracellular proteins. 224 
C. trachomatis is known to secrete hsp`s during an infection and antigenic epitopes from the 225 
bacterial hsp`s have proven to be strong inducers of cellular and humoral immunity. 226 
Chlamydial hps60 exhibits over 70% sequence homology and 100% amino acid homology of 227 
four defined epitopes with human hsp60 (3) and several studies have suggested that 228 
autoimmunity to human hsp60 is a result of cross reactivity after a chlamydial infection (27, 229 
136). However, a recent study demonstrated an association with tubal factor infertility (TFI) 230 
and antibodies to MOMP and hsp60 from C. trachomatis but no connection between TFI and 231 
antibodies to human hsp60 (49) pointing to an infectious rather than an autoimmune response 232 
as the cause of TFI.  233 
 In conclusion cell-mediated immunity that activates macrophages, neutrophils and 234 
mediators such as IL-12, IFN-γ and TNF-α is required for initial clearance. However, for 235 
protective immunity both cell-mediated and humoral immunity are needed including antigen-236 
specific T cells and antibodies that enhance uptake, processing and presentation of chlamydial 237 
antigens by DC for a rapid Th1-mediated chlamydial clearance. 238 
 239 
VACCINES 240 
 Due to increasing rates of mainly asymptomatic C. trachomatis infections worldwide 241 
and the adverse long term consequences resulting from these infections (ectopic pregnancy, 242 
infertility, preterm birth) developing an anti-chlamydial vaccine is paramount. However, a 243 
human vaccine that elicits both T cell and B cell immunity has been elusive. Although the two 244 
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murine models using C. trachomatis and C. muridarum are the most common models used for 245 
chlamydial vaccine research non-human primates, pigs and guinea pigs have also been 246 
utilized (24). Our poor understanding of the immune response in the female genital tract, 247 
which is highly regulated by sex hormones during the menstrual cycle (52), the lack of 248 
adjuvants that not only optimize the immune response to Chlamydia antigens but can target 249 
the vaccine-specific-immune responses to the site of infection and limited understanding of 250 
what type of chlamydial antigens induce a protective immune response hinder the 251 
development of a human C. trachomatis vaccine. C. trachomatis vaccine has to induce both 252 
mucosal and systemic immune responses, but autoimmune cross reactions with human 253 
antigens and unregulated inflammation that causes pathology has to be avoided. Table 2 254 
summarizes recent chlamydial antigens, delivery systems, routes of vaccination and infection 255 
and the subsequent immune responses elicited.  256 
Intact attenuated organisms 257 
 Successful vaccines against ovine enzootic abortions have been available for many 258 
years (32). These vaccines consisted of live attenuated or inactivated C. abortis strains and 259 
provided proof of principle that a successful vaccine against Chlamydia was possible in 260 
mammals. However, these vaccines did not prevent infectivity and lacked the rigorous 261 
immunization schedules, efficacy, safety and toxicity standards required for human vaccine 262 
(56, 85). Nonetheless, because of the success of these vaccines, live attenuated C. trachomatis 263 
bacteria were used as the first human Chlamydia vaccines (43). Attenuation was induced by 264 
either mutagenesis or by growing the organisms in culture. In the latter approach, after several 265 
passages, one or more mutations arise, which may result in a nonvirulent attenuated strain. 266 
Vaccines with live organisms are generally considered optimal because they contain virtually 267 
all of their antigenic determinants in the correct three dimensional conformation. Moreover, 268 
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they replicate similarly to the target pathogen thus promoting the processing and presentation 269 
of antigens similar to natural infection and eliciting humoral and cell-mediated immunity. 270 
However, using live attenuated organisms for vaccines has drawbacks because large scale 271 
production of pure Chlamydia is extremely complex and these vaccines need cold storage. 272 
Even more importantly, they can also revert to virulent wild-type strains resulting in disease 273 
or persistent infection (26).  274 
 Initial vaccine human trials using live attenuated C. trachomatis led to partial short-275 
lived protection, however some individuals who were re-exposed to Chlamydia developed a 276 
more severe pathological delayed-type hypersensitivity  (DTH)  response than those that did 277 
not receive the vaccine (43). Because of the safety issues of live vaccines, research switched 278 
to organisms that were heat or chemically-inactivated. The major disadvantage of these types 279 
of vaccines is the absence of replication and poor induction of cell-mediated immunity, which 280 
is critical for the clearance of Chlamydia, necessitating the need for re-vaccination and 281 
adjuvants. Heat or chemical bacterial inactivation may also release unwanted and detrimental 282 
components which can have deleterious effects or degrade protein antigenic determinants 283 
thereby reducing the degree of protection.  Recently, plasmid-deficient Chlamydia strains 284 
have been used in vaccine research with conflicting results. O`Connell et al. demonstrated 285 
that a plasmid-deficient strain of C. muridarum (Nigg) that is defective in its ability to 286 
accumulate glycogen did not cause inflammatory pathology in mice. Furthermore, the 287 
plasmid-deficient bacterium protected mice against a secondary infection with plasmid-288 
competent virulent C. muridarum (97). However, a different group demonstrated that mice 289 
vaccinated with an attenuated plasmidless C. trachomatis (L2R) were not protected from 290 
colonization and inflammatory pathology after a secondary challenge with wild-type C. 291 
trachomatis (serovar D) although there was a reduction in infectious burden at early time 292 
points (100).  293 
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Subunit antigenic determinants 294 
Another vaccine strategy utilized is the administration of purified antigenic 295 
determinants known to elicit an immune response. Subunit vaccines are safer than attenuated 296 
or heat/chemically inactivated organisms because they cannot revert to a virulent form and 297 
undesirable antigens that might induce immunopathology can be avoided. One of the most 298 
studied vaccine candidate for C. trachomatis is the structurally and immunologically 299 
dominant protein in the chlamydial outer membrane MOMP. This membrane protein contains 300 
several conserved CD4+, CD8+, and B cell epitopes (96) . An early study conducted by Pal 301 
and colleagues demonstrated that C. muridarum COMP (chlamydial outer membrane 302 
complex),  a chlamydial outer membrane with a cysteine cross-linked protein shell, 303 
significantly protected mice against genital challenge whereas MOMP did not (108). Several 304 
years later the same group administered purified and refolded preparation of C. muridarum 305 
MOMP along with Freund`s adjuvant. The refolded MOMP-Freunds adjuvant conferred a 306 
significant level of protection in the vaccinated mice against a genital infection demonstrating 307 
the importance of adjuvants and a correct MOMP configuration in eliciting a protective 308 
immune response (109). Tiffrea et al. discovered that a polymer that keeps membrane proteins 309 
soluble (amphipol) in aqueous solution was able to stabilize MOMP and enhance its 310 
protective ability as a vaccine (128). Another group immunized mice with a C. trachomatis 311 
MOMP-ISCOM vaccine. ISCOM (immune stimulating complex) which are mainly composed 312 
of cholesterol, phospholipids and saponin, are known to induce both a cell-mediated and 313 
humoral response when used as vaccine adjuvants. Inoculation with MOMP-ISCOM was able 314 
elicit a Th1 antigen-specific response and vaginal infection was cleared within one week (58). 315 
A C. muridarium MOMP native preparation combined with an adjuvant consisting of 316 
nontoxic subunit B cholera toxin conjugated to CpG (CTB-CpG) elicited a significant cell 317 
14 
 
mediated and antigen-specific antibody response against a pulmonary challenge with C. 318 
muridarum (18). A non-human primate model was used to demonstrate the efficacy of a 319 
vaccine formulated with native MOMP. Rhesus macaques that were immunized 320 
intramuscularly and subcutaneously along with the adjuvants CpG-2395 and Montanide ISA 321 
720 produced high levels of Th1 cytokines (INF-γ, TNF-α) and C. trachomatis-specific IgG 322 
and IgA (19). Drawbacks of subunits vaccines include the fact that extracting, refolding and 323 
purifying protein complexes such as MOMP is very expensive and purifications are not 324 
standardized so difference in extraction methods may influence the conformation of the 325 
protein epitopes and vaccine efficacy. 326 
Recombinant proteins 327 
 The advent of recombinant DNA technology has made it possible to produce large 328 
quantities of bacterial proteins. Thus, different attempts were made to use rMOMP in C. 329 
trachomatis vaccine. Unfortunately, producing rMOMP with its native conformational 330 
epitopes intact on a large scale is challenging and in some expression systems full-length 331 
rMOMP is toxic (78, 147). In 2009, a comparison of vaccines using native or recombinant 332 
MOMP demonstrated that the degree of protection obtained with recombinant MOMP was 333 
not as robust as that achieved with native MOMP preparation (123). However, other studies 334 
using rMOMP with and without adjuvants demonstrated protection against Chlamydia (98, 335 
127). In 2011, Kalbina and colleagues designed a chimeric gene construct containing two 336 
antigenic regions of MOMP and introduced the construct into a bacteria (Escherichia coli) 337 
and two plants (Arabidopsis thaliana, Daucus carota). The construct was successfully 338 
expressed in E. coli, and stable integration of the transgene was demonstrated in A. thaliana 339 
and D. carota over several generations. The rMOMP purified from E. coli was used to 340 
produce antibodies in rabbits and these antibodies recognized the proteins in both E. coli, A. 341 
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thaliana, D. carota as well as in inactivated C. trachomatis elementary bodies. The stability 342 
of the construct in the offspring plants suggests that this system may be useful for large scale 343 
production of rMOMP and the authors plan to use the transgenic plants as edible vaccine 344 
vectors for laboratory animal experiments (67). 345 
 Other recombinant proteins besides MOMP have also been shown to be potential 346 
vaccine candidates. In 2007,  Murphy et al. investigated the potential of recombinant CPAF to 347 
elicit an immune response that would resolve chlamydial infection. Mice immunized 348 
intranasally with rCPAF and IL-12 (Th1 cytokine) demonstrated increased IFN-γ, and 349 
minimal IL-4 (Th2 cytokine) production, elevated IgG2a (Th1) and IgA (mucosal) antibody 350 
levels, displayed a markedly reduced bacterial burden upon C. muridarum genital inoculation 351 
and were protected against pathological consequences of Chlamydia infection compared with 352 
mock immunized mice (91). The same group demonstrated that rCPAF intranasal vaccination 353 
may prevent infertility from repeated genital C. muridarum infections in mice (93). Mice 354 
immunized with a recombinant chlamydial glycogen phosphorylase (GlgP) and intravaginally 355 
challenged with live C. muridarum elicited a Th1-dominant T cell response that included anti-356 
chlamydial antibodies and reduced hydrosalpinx severity. Additionally, the GlgP-immunized 357 
mice exhibited a significant reduction of vaginal shedding on day 14 post-infection (76). 358 
Olsen et al. utilized two recombinant proteins in a subunit chlamydial vaccine. The fusion 359 
protein CTH1 consisted of CT443 (omcB) which is known to elicit both a humoral and cell-360 
mediated response and CT521 (rl 16) a known target for cells during natural infection in 361 
humans. Immunization with CTH1 along with the strong Th1 inducing adjuvant CAF01 362 
elicited TNF-α, IL-2 and INF-γ production from T cells and high titers of both Th1 (IgG2a) 363 
and Th2 (IgG1) CTH1-specific antibodies. The vaccine significantly reduced bacterial 364 
shedding after a vaginal challenge with live C. trachomatis and C. muridarum and protection 365 
was demonstrated to be solely CD4+ T cell-mediated in the C. muridarum model (102). Lu 366 
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and colleagues screened 5 recombinant chlamydial antigens (ABC transporter [ArtJ], outer 367 
membrane complex protein B [OmcB], macrophage infectivity potentiator [Mip], inclusion 368 
membrane protein [Inc (crpA:TC0726)], and an hypothetical protein), that were previously 369 
found to react with sera from intravaginally C. muridarum infected mice for their ability to 370 
induce protection against chlamydial infection. Only Mip induced pronounced protection 371 
which was characterized by Th1-dominant T cell response and anti-Mip antibodies (80). 372 
Plasmid DNA 373 
 DNA vaccines work by injecting a plasmid that encodes a specific gene of interest 374 
within the host. The product of the gene can then be expressed inducing an immune response. 375 
DNA vaccines have several advantages compared with other vaccination strategies. DNA can 376 
be easily and inexpensively purified and plasmid vectors can be rapidly constructed and easily 377 
tested (79). Additionally, DNA vaccines can encode for multiple epitopes that are in the 378 
native three dimensional configuration and avoid the problem associated with attenuated 379 
organisms which are able to revert back to virulent forms. However, as with other vaccine 380 
strategies, DNA vaccines have some disadvantages. In autoimmune diseases such as lupus 381 
anti-DNA antibodies are produced and there is the possibility that bacterial DNA injection 382 
could elicit a humoral response that cross-reacts with the host DNA. Also, because DNA 383 
encodes for proteins, DNA vaccines cannot be utilized for non-protein based antigens such as 384 
polysaccharides or lipids (73) and although likely rare, there is the risk that  DNA could 385 
integrate into the host chromosome (35). In 1999 Pal and colleagues immunized mice with a 386 
DNA vaccine that encoded for the MOMP gene of C. trachomatis. When the mice were 387 
vaginally challenged with C. trachomatis the immune response was modest and the mice were 388 
not protected against infection (106). The following year Dong-Ji et al. demonstrated that 389 
immunization with DNA-MOMP and boosting with MOMP-ISCOM conferred higher 390 
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protection against C. trachomatis when compared with mice that were only immunized with 391 
MOMP-ISCOM (28). More recently two studies using a pig model assessed the efficacy of 392 
DNA chlamydial vaccines. Schautteet et al. combined aerosol-vaginal delivery of DNA 393 
vaccine encoding for MOMP co-administered with DNA encoding for three different 394 
adjuvants (GM-CSF, E. coli enterotoxin subunit A and B). Vaccination induced significant 395 
protection against genital C. trachomatis challenge although the infection was not completely 396 
resolved (117). Ou and colleagues demonstrated that an OmpA-based DNA vaccine against 397 
Chlamydia abortus in piglets elicited higher antigen-specific IgG antibodies and T cell 398 
proliferative response compared with controls (105). Mammalian cells transfected with a 399 
plasmid encoding for MOMP epitopes inserted in a human papillomavirus (HPV) major 400 
capsid protein L1 was used in a murine model of C. trachomatis genital infection. 401 
Intramuscular administration elicited a Th1 response characterized by low IL-4 production 402 
and antibodies against MOMP (139). All of these recent studies demonstrate the feasibility of 403 
DNA-based vaccine and this approach thus  deserves further study. 404 
 405 
OTHER CHLAMYDIAL VACCINES AND DELIVERY SYSTEMS 406 
Bacterial ghosts 407 
  Bacterial ghosts (BGs) are cell envelopes derived from Gram-negative bacteria. BGs 408 
are devoid of all cytoplasmic content but have a preserved cellular morphology including all 409 
cell surface structures. BGs are non living but retain all of the antigenic components of their 410 
living counterparts and the inside of the BG envelope can be loaded with peptides, drugs, or 411 
DNA (74). In 2007, a vaccine system in which a DNA plasmid that encoded for C. 412 
trachomatis MOMP and the porin protein (PorB) was inserted into a recombinant Vibrio 413 
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cholerae ghost (rVCG) was used.  Animals that were immunized intramuscularly with the 414 
DNA-bacterial ghost vaccine completely resolved a C. trachomatis genital infection after two 415 
weeks post-infection. The inflammatory response was Th1, characterized by high levels of 416 
IgA and IgG2a (55). More recently, Eko and colleagues used the rVCG that contained PorB 417 
and chlamydial polymorphic membrane protein-D (PmpD) proteins to evaluate its ability to 418 
induce chlamydial immunity. Intramuscular immunization elicited high levels of Th1-419 
associated antibody IgG2a, mucosal-associated antibody IgA, IFN-γ (Th1) and low levels of 420 
IL-5 (Th2) in response to an intravaginal C. muridarum infection  (31).  421 
Biodegradable polymers 422 
 PLGA (poly D, L-lactide-co-glycolide) is an FDA approved polysaccharide that can 423 
encapsulate peptide, proteins or DNA. PLGA`s are efficiently phagocytosed by DC and 424 
macrophages (83, 134) and PLGA antigens are able to be presented on both MHC class I and 425 
II molecules thus activating CD4+ and CD8+ T cells (45, 133). Chitosan is a linear 426 
polysaccharide derived from the deacetylation of chitin. The glucosamine units of chitosan 427 
have a density of amine groups which permits strong electrostatic interactions with proteins 428 
and genes. Additionally chitosan is mucoadhesive and has enhanced penetration capacity 429 
across mucosal barriers.(10). Both of these nanoparticles are biodegradable, relatively non-430 
toxic and have been used as delivery systems for chlamydial vaccines. Two recent studies 431 
using recombinant MOMP encapsulated in PLGA demonstrated enhanced capacity of the 432 
peptide to induce Th1 cytokine, cellular and antibody immune response (33, 125). Cambridge 433 
et al. demonstrated that MOMP was expressed in the muscle tissues and spleens of mice that 434 
were intramuscularly injected with chitosan nanoparticles containing recombinant MOMP 435 
DNA (14).  436 
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Gas vesicles 437 
Gas vesicles are gas containing structures found in some bacteria and Archaea. These protein 438 
structures are hollow, rigid, lipid-free, allow diffusion of gases across its membrane, and are 439 
able to express peptides from various genes. Studies have shown that in the absence of 440 
adjuvants, Halobacteria gas vesicles that displayed viral peptides elicited robust long-lived 441 
immune response characterized by immunological memory in mice (120). Halobacteria-442 
derived gas vesicles that were loaded with gene fragments coding for MOMP, OmcB (outer 443 
membrane complex B), and PompB (polymorphic outer membrane B) and expressed on the 444 
surface were able to elicit a Th1 cytokine profile in human foreskin fibroblasts in vitro. In 445 
addition the presence of the recombinant proteins were confirmed by anti-Chlamydia 446 
antibodies and from Chlamydia-positive patient serum suggesting this could be an effective 447 
antigen delivery system for a Chlamydia vaccine (20). 448 
 449 
ADJUVANTS 450 
 Adjuvants enhance immunity and one of the main challenges in developing an 451 
effective chlamydial vaccine is identifying antigen/adjuvant combinations that elicit a 452 
protective immune response in vivo. Various adjuvant such as the ones mentioned in this 453 
review (e.g. Freund`s adjuvant, ISCOM`s, CTB-CpG, CpG, bacterial ghosts) have been used 454 
in chlamydial vaccine research with varying results. Recent research has added other new 455 
antigen/adjuvant candidates with encouraging results. A study by Yu and colleagues 456 
evaluated the chlamydial protein PmpG and five adjuvants, including three cationic liposome 457 
formulations, Montanide ISA720-CpG-ODN1826 and alum. The results demonstrated that the 458 
cationic liposomal adjuvants DDA-MPL and DDa-TDB elicited the best protective immune 459 
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responses against C. muridarum. Additionally, using DDA-MPL as an adjuvant along with 7 460 
different T cell antigens (PmpG, PmpE, Aasf, Rp1F, TC0420, TC0825) conferred equal or 461 
better protection than the vaccine antigen MOMP alone (142). This highlights the various 462 
opportunities to further improve vaccine candidates by identifying the optimal 463 
epitope/adjuvant combination 464 
 465 
VACCINATION ROUTES 466 
 Vaccine efficacy is not only defined by the type of antigen and adjuvant used but also 467 
by the administration route, since lymphocytes primed by antigens in vivo are endowed with 468 
specialized homing programs guiding their migration to specific mucosal sites (95). Once 469 
naive T cells are primed in a lymph node, a global switch of their homing program occurs 470 
which enables them, while trafficking through the blood circulation, to detect chemokines and 471 
adhesion molecules which direct them to their tissue destination. Lymphocytes,  activated by 472 
antigen presentation occurring in lymph nodes draining a mucosal site, acquire specialized 473 
homing programs leading them to preferentially migrate to the same or other specific mucosal 474 
sites.  Of note, T cell homing to the genital mucosa involves either α1β1, α4β1 (110) or 475 
α4β7/E selectin (70) in Chlamydia infected mice. Both systemic and mucosal immunization 476 
routes have been shown to be able to induce both humoral and cell-mediated immune 477 
responses in the genital tract with intranasal immunization being often more effective (11, 478 
94). Overall, mucosal immunization routes were more effective at preventing genital 479 
challenges with a variety of pathogens (37, 44, 63, 77, 144).  480 
 Numerous immunization routes have been used for chlamydial vaccinations including 481 
oral (48), intranasal (i.n.) (46), intravaginal (i.vag) (118), subcutaneous (107),  intramuscular 482 
(30),  perivaginal (107),  perisacral (107), sublingual v(113)  and colonic (16). A study using 483 
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purified MOMP with a Borrelia surface protein as an adjuvant demonstrated that in two 484 
different mouse strains "intramuscular + subcutaneous" and "perivaginal + perisacral" 485 
immunization elicited high systemic (IgG) and mucosal (IgA) serum antibodies. In contrast, 486 
the mice that received the MOMP-adjuvant i.n. had low IgG and IgA serum antibodies (107). 487 
However, a recent study showed that i.n. immunization with rMOMP resulted in MOMP-488 
specific IgA and IgG antibodies in genital tract secretions demonstrating i.n. administration 489 
may target immunity to the reproductive tract (23). Several studies comparing the protective 490 
ability of various vaccination routes demonstrated that a combined mucosal and systemic 491 
inoculation may be optimal. Using rMOMP with the adjuvants CpG and Montanide for 492 
systemic route (intramuscular and subcutaneous) and rMOMP with cholera toxin for the 493 
mucosal routes (sublingual and colonic), the authors demonstrated that following i.n. C. 494 
trachomatis challenge the sublingual + intramuscular + subcutaneous group showed the best 495 
protection (113). Another group demonstrated that mice immunized by combined mucosal 496 
and systemic routes with C. muridarum recombinant MOMP plus the adjuvants CpG and 497 
Montanide not only elicited the strongest chlamydia-specific humoral and cell-mediated 498 
response after vaginal challenge with C. muridarum  but also protected against infertility (16).  499 
 500 
CONCLUSIONS 501 
 Chlamydial infection is a public health concern worldwide and a vaccine that 502 
stimulates multiple arms of the adaptive immune system and avoids immunopathological 503 
consequences would be the best solution for the control of this sexually transmitted disease. 504 
Unfortunately, a partial or fully protective vaccine has yet to be developed highlighting the 505 
complex nature of the immunobiology mounted against this intracellular parasitic bacterium. 506 
The immune response to chlamydial infection is dynamic and involves cells and mediators 507 
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from both arms of the host’s immune system. Clearance of a chlamydial infection requires a 508 
coordinated immune response between innate immune cells such as macrophages, DC and 509 
cells important in both cell-mediated and humoral adaptive responses such as CD4+T cells, 510 
CD8+ T cells and B cells. Activation and clonal expansion of T cells occurs through cognate 511 
interactions with DC that present chlamydial antigens on their MHC molecules and B cells 512 
produce anti-chlamydial antibodies through interaction with these clonal T cells. However, 513 
persistent infection seems to induce chronic inflammation and tissue damage. A shift from 514 
Th1 to Th2 also appears to induce scarring and immune pathology. It is therefore essential to 515 
understand these immunological dynamics in order to develop a vaccine that is both effective, 516 
long-lasting and does not have the deleterious effects associated with unregulated 517 
inflammation. Further research is needed to identify novel adjuvants that enhance the immune 518 
response and antigens that induce a protective T cell response and anti-chlamydial antibodies.  519 
 A mathematical model developed by Gray and colleagues demonstrated that a fully 520 
protective vaccine, administered to adolescents before they are sexually active, would be able 521 
to eradicate Chlamydia infection in 20 years. In addition, the model predicted that vaccinating 522 
100% of women would have a greater epidemiological impact than vaccinating both sexes 523 
(42). Unfortunately there are risks and ethical questions associated with vaccination programs 524 
as demonstrated by the first Chlamydia vaccine using live attenuated bacterium (43). Thus, 525 
research is needed to develop an efficient and safe chlamydial vaccine. 526 
 527 
  528 
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Table 1.  Summary of recent developments in chlamydial research including chlamydial strain/antigen utilized, cell type infected and immune response elicited 
Cell type Chlamydia/Antigen Immune Response Ref. 
Mouse macrophage cell line (J774) 
and human macrophages 
 
Mouse (RAW) and human (THP-1)  
macrophage cell line 
 
Human macrophages 
 
C. trachomatis 
 
 
C. trachomatis 
 
 
C. trachomatis 
• Live and inactivated Chlamydia induced elevated IL-8, IL-1β, TNF-α, IL-6. 
 
 
• Live Chlamydia induced autophagy. 
 
 
• Live Chlamydia infected macrophages induced T cell apoptosis. 
(3, 24) 
 
 
(1, 22) 
 
 
(10, 11) 
Mouse BMDC 
 
 
 
 
Mouse BMDC 
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Mouse BMDC 
 
 
 
 
Mouse BMDC 
 
 
 
Mouse BMDC 
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C. muridarum 
 
 
 
 
rMOMP 
 
 
C. trachomatis 
 
 
C. muridarum 
 
 
 
 
C. muridarum 
 
 
 
Recombinant adenovirus 
carrying C. trachomatis 
MOMP 
 
UV C. muridarum + CpG 
or  rCPAF + CpG 
• DC pulsed with UV-inactivated Chlamydia in vitro secreted elevated levels of IL-12. 
• DC pulsed with UV-inactivated Chlamydia and adoptively transferred into naive mice induced strong protection against live 
chlamydial lung infection. 
• IL-12-/- DC failed to induce Th-1 dominant response and did not induce strong protection against chlamydial infection. 
 
• DC pulsed with rMOMP secreted IL-12 and induced infection-sensitized CD4+T cells to secrete IFN-γ. 
• DC pulsed with rMOMP and adoptively transferred into naive mice generated a Th2 anti-MOMP immune response. 
 
• IL-10-/- DC pulsed with UV-inactivated Chlamydia caused early DC  maturation, activation, increased ability to process and present 
antigens and enhanced the rate of Th1 activation. 
 
• DC incubated with UV-inactivated Chlamydia  expressed low levels of CD40 and CD80, secreted low levels of proinflammatory 
cytokines and exhibited reduced recognition by Chlamydia-specific CD4+ T cells. 
• Adoptive transfer of live EB-pulsed DC was more effective that UV Chlamydia at protecting mice against a live intranasal chlamydial 
challenge. 
 
• DC pulsed with live EBs presented 45 MHC class II C. muridarum peptides mapping to 13 proteins. In contrast DC pulsed with heat 
or UV-inactivated Chlamydia presented only six MHC class II chlamydial peptides mapping to 3 proteins.  
• Only two epitopes were shared in common between live and inactivated C. muridarum. 
 
• DC exhibited increased CD80 and MHC class II, IL-12 and were able to stimulate CD4+ T cell proliferation and IFN-γ.  
• Adoptively transferred MOMP transfected DC generated Th1-biased cytokine production, mucosal IgA  and protected mice against 
chlamydial genital tract infection. 
 
• DC pulsed with rCPAF + CpG exhibited increased CD86, CD80, CD40, MHC class II, IL-12 but not IL-10 and IL-4. 
• Mice adoptively immunized with rCPAF + CpG or UV C. muridarum + CpG pulsed DC produced elevated IFN-γ, IG1, IgG2a and 
exhibited reduced Chlamydia shedding and reduced oviduct pathology compared to infected mock-immunized mice. 
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(21) 
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(20) 
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(13) 
 
 
 
(12) 
Mouse T cells 
 
Mouse T cells 
 
 
 
 
Mouse T cells 
 
 
Mouse CD4+ T cells 
 
 
Mouse CD4 + T cells 
 
 
Human CD4+ T cells 
 
 
Mouse CD8+ T cells 
 
 
Human CD8+ T cells 
C. muridarum 
 
C. trachomatis T cell 
antigens + AbISCO-100  
 
 
 
C. muridarum MOMP + 
CpG and Montanide ISA 
 
C. trachomatis 
 
 
C. muridarum 
 
 
C.  trachomatis 
 
 
C. muridarum 
 
 
C. trachomatis 
 
• Athymic nude mice established chronic genital tract infection whereas wild-type mice resolved infection in 20 days. 
 
• Potent CD8+ T response, polyfunctional Th1-polarized CD4+ T cell responses (INF-γ, TNF-α, IL-2) and high protein specific Th1-
skewed antibody response (IgG2c).  
• Adoptive transfer of CD4+ T cells and CD8+ T cells to naive non-immunized mice protected against C. trachomatis vaginal challenge 
whereas passive transfer of immune sera did not. 
 
• Vaccinated mice were depleted of CD4+ and CD8+ T cells and challenged vaginally with live C. muridarum. Depletion of CD4+ T  
cells, but not CD8+ T cells diminished vaccine-induced protection. 
 
• Genital tract C. trachomatis infection stimulated the activation and memory development of C. trachomatis-specific CD4+ T cells. 
• CD4+ T cells are necessary to confer protection against C. trachomatis infection. 
 
• CD4 T cell clone-induced epithelial NO production was critical for controlling replication. 
• Most potent CD4+ T cell clones were dependent on T cell degranulation for chlamydial replication control. 
 
• CD4+ T cells from women with genital tract infection that were pulsed ex vivo with EB secreted significantly more IL-4 than TNF-α 
and INF-γ. 
 
• TNF-α from CD8+ T cells contributed significantly to oviduct pathological sequelae, but not bacterial clearance, following genital 
chlamydial challenge. 
 
• Endocervix effector memory CD8+ T cells from C. trachomatis infected women expressed low perforin levels. 
(19) 
 
(18) 
 
 
 
 
(4) 
 
 
(6) 
 
 
(9) 
 
 
(23) 
 
 
 
(17) 
 
(8) 
Human B cells/Antibodies 
 
Mouse B cells/Antibodies 
 
 
 
 
Mouse B cells/Antibodies 
 
 
 
Mouse B cells/Antibodies 
 
Recombinant outer 
membrane vesicles 
carrying C. muridarum 
HtrA 
 
C. muridarum or 
MOMP monoclocal 
antibody (mAb) 
 
rCPAF + CpG  
 
• Identified 21 antibody inducing antigens from C. trachomatis-infected patients sera. 
 
• Mice immunized with outer membrane vesicles carrying HtrA induced anti-HtrA-specific antibodies that neutralized C. muridarum  
infectivity in vitro. 
 
 
 
• Passive immunization with serum from C. muridarum infected mice conferred a marked level of protection from C. muridarum 
genital reinfection and shortened the time of infection. 
• MOMP mAbs conferred significant level of immunity to reinfection and reduced shedding. 
 
• Both wild-type and B cell deficient (μmT) mice vaccinated intranasally with rCPAF + CpG and challenged with live C.  muridarum 
vaginally demonstrated comparable clearance and similar reductions in pathology. 
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(15) 
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Table 2.  Summary of recent developments in chlamydial vaccine research  
 Vaccines Advantages Disadvantages Ag/Adjuvants Ag 
Immunization 
Route 
Model/ 
Chlamydia 
Infection 
Route 
Immune Response Ref. 
Intact 
Chlamydia 
• Intact Ag 
• Native 
configuration 
• Replication 
• Humoral/Cellular 
immunity 
 
• Requires 
refrigeration 
• Potential 
reverting to 
virulent strains 
• Large scale 
production 
difficult 
• Possible 
transmission to 
unvaccinated 
individuals 
 
 
Plasmid-deficient Chlamydia 
(CM972, CM3.1) 
 
 
 
Plasmid-Deficient Chlamydia 
(L2) 
 Mouse / i.v. 
 
 
 
 
Mouse / i.v 
• Elevated IgG2a (Th1); low levels of IgG1 (Th2) 
• Mutants do not stimulate TLR2-dependent cytokine production 
• Infected mice with mutant Chlamydia and challenged with wt Chlamydia 
are protected against oviduct disease 
 
• Elevated IgG2a;  low IgG1; no IgA (mucosal) 
• No pathology in the urogenital tract induced by L2 
• Mice vaccinated with plasmid-deficient bacterium were not protected 
from infection/inflammation with secondary wt chlamydial infection 
(17) 
 
 
 
 
 
(19) 
Purified 
Subunits 
• Do not revert to 
virulent strains 
• Avoids 
undesirable 
antigens 
• Expensive to 
produce 
• Purification not 
standardized 
• Difficult to 
maintain native 
conformation of 
antigen 
complex 
MOMP + subunit B cholera 
toxin conjugated to CpG 
 
MOMP-ISCOM 
 
MOMP + Freund`s adjuvant 
 
 
MOMP + IC31 
 
MOMP + CpG/Montanide 
i.m. + s.c. 
 
 
i.n. or i.m. 
 
i.m + s.c 
 
 
i.m + s.c 
 
i.m + s.c 
Mouse / i.n. 
 
 
Mouse / i.n. 
 
Mouse / i.v. 
 
 
Mouse / i.n. 
 
Rhesus 
macaque 
• Elevated IgG2a, IgG3 (Th1);  lower IgG1 
• Elevated INF-γ (Th1) 
 
• i.m. induced highest INF-γ and IL-4 (Th2) 
 
• Vortexed MOMP elicited higher IgG2a vs IgG1 
• Sonicated MOMP elicited higher IgG1 vs IgG2a  
 
• Higher IgG1 than IgG2a 
 
• Elevated IgG ,IgA, INF-γ and TNF-α 
(2) 
 
 
(10) 
 
(23) 
 
 
(3) 
 
(4) 
Recombinant 
Proteins 
• High yields 
• Inexpensive 
• Some proteins 
require post-
translational 
modification 
• If produced in 
E. coli 
possibility of 
endotoxin 
contamination 
rMOMP + Cholera toxin/CpG 
or CTA1 
 
 
 
 
rMOMP + CpG /Montonide  
 
 
rCPAF + IL-12 
 
 
rCPAF + CpG 
 
rCTH1 + CAF01 
 
 
 
rGlgP + CpG 
 
 
rMIP 
s.l. or t.c. or 
i.n. 
 
 
 
 
i.m + s.c. 
 
 
i.n. 
 
 
i.n. 
 
s.c. 
 
 
 
i.m. 
 
 
i.m. 
Mouse / i.n. 
 
 
 
 
 
Mouse / i.n. 
 
 
Mouse / i.v. 
 
 
Mouse / i.v. 
 
Mouse / i.v. 
 
 
 
Mouse / i.v.  
 
 
Mouse / i.v. 
• Elevated IFN-γ and TNF-α 
• i.n. immunization with MOMP + either adjuvant protected mice from 
infection but not pathology 
• t.c. immunization with MOMP and CTA1-DD protected mice from 
pathology but Chlamydia burden was same as control mice 
 
• Vaccination protected against fibrotic scarring in lungs 
• Elevated IgG2a and lower levels of IgG1 
 
• Increased IFN-γ ; minimal IL-4  
• Elevated IgG2a and IgA  
 
• Vaccination significantly prevented infertility 
 
• T cell production of TNF-α/IL-2/IFN-γ 
• anti-CTH1 IgG2a, IgG1  
• Protection was solely CD4+T cell-mediated 
 
• Th1-dominant T cell response 
• Reduced hydrosalpinx severity 
 
• More IgG2a vs IgG1 
(18) 
 
 
 
 
 
(27) 
 
 
(15) 
 
 
(16) 
 
 
(20) 
 
 
 
(12) 
 
(13) 
rCT043 
 
 
 
rCT823 + ISCOM and 
CT144 + ISCOM 
i.m. 
 
 
 
s.c. 
Mouse / i.n. 
 
 
 
Mouse / i.v. 
• Elevated IFN-γ and no IL-4 
• Reduced hydrosalpinx severity 
• rCT043 reduces bacterial load in a mouse model of i.n. infection 
 
• Elevated INF-γ, TNF-α, IL-2 
• No detectable IL-4 and IL-10 
• Elevated IgG2c (Th1) but not IgG1 
(14) 
 
 
 
(24) 
 
 
DNA Vaccines • Cheap 
• Easy to produce 
• Can encode for 
multiple epitopes 
• Native 
conformation of 
antigenic 
determinants 
• Safety 
• Possible 
genome 
integration 
• Anti-DNA 
antibodies 
• Not possible for 
non-proteins 
DNA MOMP 
 
Priming with MOMP and 
secondary boost with DNA 
MOMP-ISCOM 
 
DNA MOMP + GM-CSF, 
enterotoxin (E. coli) A & B 
 
 
 
 
ompA 
i.m. 
 
i.m. 
 
 
 
i.n.  + i.v. 
 
 
 
 
 
i.m. 
Mouse / i.v. 
 
Mouse / i.n. 
 
 
 
Pig / i.v. 
 
 
 
 
 
Pig / i.m. 
• Elevated levels of IgG2a and IgG1 
 
• Elevated levels of IgG2a, IgA and IFN-γ 
 
 
• Vaccination induced significant protection against genital challenge 
• Protection correlated with efficient T cell priming and elevated IgA 
• anti-MOMP antibodies and low IL-4 production 
 
 
(22) 
 
(6) 
 
 
(25) 
 
 
 
 
 
 
(21) 
Bacterial 
Ghosts 
• Inactivation not 
required therefore 
relevant antigenic 
determinants are 
not denatured 
• Easy to produce 
• Require no 
refrigeration 
• Carriage of 
different antigens, 
DNA and drugs 
simultaneously 
• Recognition and 
phagocytosis by 
APC 
• Presence of 
LPS 
MOMP & PorB DNA plasmid 
 
PmpD &  PorB DNA plasmid  
i.m. 
 
i.m. 
 
Mouse / i.v. 
 
Mouse / i.v. 
 
• High levels of IgG2a and IgA  
 
• High levels of IgG2a and IgA, IFN-γ and low levels of IL-5 (Th2) 
 
(9) 
 
(7) 
Biodegradable 
Polymers 
• Biodegradable 
• Non-toxic 
• High 
encapsulation 
capacity 
• PLGA`s are 
efficiently 
phagocytosed by 
DC and 
macrophages 
• Chitosan has 
mucosal 
adhesiveness 
properties and 
enhanced 
penetration 
across mucosal 
barrier 
 rMOMP encapsulated in 
PLGA 
 
 
Chitosan containing rMOMP 
DNA 
s.c 
 
 
 
i.m. 
Mouse • Elevated CD4+ and CD8+ T cells 
• Elevated INF-γ, IL-12; reduced IL-4, IL-10 
• Elevated IgG2a; reduced IgG1 
 
 
(8, 26) 
 
 
 
(1) 
Vaccines from 
Transgenic 
Plants 
• Low cost 
production 
• Ease of use 
• Requirement for 
strong adjuvant 
MOMP introduced into A. 
thaliana and D. carota 
 (11) 
Gas Vesicles • Able to express 
peptides from 
various genes 
 Gen fragments coding for 
MOMP, OmcB, Pomp loaded 
into Halobacteria-derived gas 
vesicles 
• Elicited Th-1 cytokines in human foreskin fibroblasts (5) 
* i.m. (intramuscular), s.c. (subcutaneous), i.n. (intranasal), s.l. (subligual),  t.c. (trancutaneous), i.v. (intravaginal) 
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